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Abstract
The recently cloned type II receptor protein tyrosine phosphatase (RPTP) gene hPTP-J is a new member of the MAM
(meprin, A5, PTPW) domain subfamily. We previously reported that hPTP-J mRNA was detected significantly in Jurkat T
lymphoma cells and its expression was completely down-regulated by phorbol myristate acetate (PMA). In this study, we
investigated what signaling pathways/molecules are involved in the transcriptional regulation of hPTP-J expression in Jurkat
and Molt-4 T cell lines. The hPTP-J transcription was transiently up-regulated 20 min after the addition of PMA (20 ng/ml)
to the Jurkat culture, followed by the complete down-regulation in 8 h after PMA addition. The transient up-regulation and
the complete down-regulation induced by PMA was blocked by a PKC-specific inhibitor, GF109203X, suggesting that the
regulatory effect of PMA on the hPTP-J transcription depends on protein kinase C activation. hPTP-J transcription was
down-regulated not only by PMA but also by several signaling modulators including 1-oleoyl-2-acetylglycerol, forskolin,
orthovanadate, manumycin and okadaic acid. Therefore, several signaling molecules such as protein tyrosine phosphatases,
PP2A/CaMKIV and Ras are required for hPTP-J transcription in Jurkat and Molt-4 cells. ß 1999 Elsevier Science B.V.
All rights reserved.
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1. Introduction
T cell activation via the T cell antigen receptor is
associated with the hydrolysis of inositol phospho-
lipids and the resultant production of inositol poly-
phosphates and diacylglycerols that regulate intra-
cellular calcium and protein kinase C (PKC),
respectively [1,2]. A phorbol ester, PMA, which
mimics diacylglycerol (DG) and activates PKC, is
metabolically stable. The cellular responses induced
by PMA are stronger than those by the endogenous
PKC activator DG because of the quick hydrolysis
of DG by lipase [3]. Besides activating PKC, PMA
also down-regulates PMA-sensitive PKC isoforms in
a time- and dose-dependent manner [4]. PMA is one
of the most intensively utilized regulators for study
of the signal transduction in various cell lines, e.g.,
PMA up-regulates CD44 expression in neuronal tu-
mors and AP1, NF-UB, CD6 and PTP1C in lympho-
cytes, but down-regulates IUB-K and platelet-activat-
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ing factor in lymphocytes [5^9]. In T lymphocytes,
phorbol esters, PKC activators, can mimic TCR trig-
gering and induce accumulation of Ras-GTP com-
plexes [10,11] but the stimulatory e¡ect of TCR
cross-linking on Ras activation is inhibited by herbi-
mycin A, a speci¢c inhibitor of protein tyrosine ki-
nases (PTKs), whereas PMA-induced Ras activation
was not a¡ected. On the other hand, calphostin C, a
speci¢c inhibitor of PKC, blocked not only PMA-
induced but also TCR-mediated formation of Ras-
GTP complexes [12]. Besides PKC, PMA could di-
rectly stimulate Vav, a guanine nucleotide exchange
factor (GEF), which is expressed speci¢cally in hem-
atopoietic cells. The activation of Vav by PMA in T
cells was independent of protein kinases but was
blocked by calphostin C in vitro and in vivo [13].
It seems that PMA can regulate many factors in T
cells.
Recently, we cloned a novel human receptor pro-
tein tyrosine phosphatase (RPTP) gene, termed
hPTP-J, encoding a 1436 amino acid glycoprotein
that consists of an extracellular region containing a
MAM (meprin, A5, PTPW)-like domain/an Ig-like
domain/four ¢bronectin type III repeats, a trans-
membrane region and a cytoplasmic region contain-
ing two tandemly repeated PTP domains [14]. Thus,
hPTP-J is considered to be a new member of the type
II receptor PTP subfamily (MAM domain RPTP
subfamily) including PTPW, PTPU, PTPZ, PCP-2
and PTPQ [15^22]. The MAM domain was character-
ized as a critical domain to mediate homophilic in-
tercellular interactions and the homophilic interac-
tion is highly speci¢c in each RPTP molecule [23^
25]. Moreover, endogenous RPTPU was found to
directly associate with L- and Q-catenins in carcinoma
cells [26]. RPTPW associated with the cadherin-cate-
nin complex in various tissues and cells [27,28].
PTPQ, a murine PTP-J gene, was cloned in murine
primitive hematopoietic cells. PTPQ was demon-
strated to mediate homotypic aggregation by MAM
and IgG domains, and associate with L-catenin via
juxtamembrane domain in kidney epithelial cells [22].
Recently, L-catenin was shown to be negatively regu-
lated by adenomatous polyposis coli (APC) tumor-
suppressor protein, and the negative control can be
abrogated by mutations in APC or L-catenin, then
allowing L-catenin to translocate to nucleus, where it
binds to lymphoid-enhancing factor-1 (LEF-1)/T cell
transcription factor (TCF), thereby activating LEF-
1/TCF-dependent transcription, e.g., c-myc oncogene
[29^33]. hPTP-J was initially cloned from cDNA de-
rived from Jurkat cells. The gene expression was,
however, undetectable in peripheral blood mononu-
clear cells and lymphoid organs including spleen and
thymus. Furthermore, the hPTP-J mRNA level in
Jurkat cells was markedly reduced by the tumor pro-
moter PMA [14]. The mechanism of the down-regu-
lation of hPTP-J transcription is still unknown in
detail. Thus, in this study, we investigated what sig-
naling pathways/molecules are involved in the tran-
scriptional regulation of hPTP-J in Jurkat and Molt-
4 T cell lines.
Here we show that hPTP-J transcription is transi-
ently up-regulated by PMA, followed by complete
down-regulation induced by PKC activation in a
newly synthesized protein-independent or -dependent
manner, respectively. The down-regulation of the
PTP-J transcription induced by okadaic acid, a
non-PMA-type tumor promoter, is supposed to be
mediated by the PP2A/CaMKIV pathway dependent
on newly synthesized proteins. Moreover, it is sug-
gested that constitutive PTP and Ras are required for
the hPTP-J transcription in Jurkat and Molt-4 cells.
2. Materials and methods
2.1. Chemical reagents
PMA (phorbol 12-myristate 13-acetate), OAG (1-
oleoyl-2-acetylglycerol), calcium ionophore A23187,
H-7 (1-(5-isoquinolinylsulfonyl)-2-methyl-pipera-
zine), cycloheximide, forskolin, thapsigargin, wort-
mannin, heparin, erbstatin, herbimycin A, GF-
109203X (bisindolylmaleimide), W-7 (N-(6-amino-
hexyl)-5-chloro-1-naphthalenesulfonamide), PDTC
(pyrrolidinedithiocarbamate), and sodium orthova-
nadate (Na3VO4) were purchased from Sigma Chem-
ical Company (St. Louis, MO, USA). 4K-PMA was
from Wako Pure Chemical Industries (Osaka, Ja-
pan). Okadaic acid was purchased from Life Tech-
nologies (Rockville, MD, USA). H-89 (N-(2-(p-bro-
mocinnamylamino)ethyl)-5-isoquinolinesulfonamide)
was from Biomol (Plymouth Meeting, PA, USA).
Anti-OKT3 mAb (anti-human CD3 mAb) was pur-
chased from Pharmingen (San Diego, CA, USA).
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Manumycin was kindly supplied from Kyowa Hakko
Ltd. (Tokyo, Japan).
2.2. Cell lines and stimulation
Human tumor cell lines used in this work are as
follows: CCRF CEM (acute lymphoblastic leuke-
mia), HL-60 (promyelocytic leukemia), HUT 78 (cu-
taneous T cell lymphoma), Jurkat (acute T cell leu-
kemia), MOLT-4 (acute lymphoblastic leukemia),
U-937 (histiocytic lymphoma), all obtained from
ATCC (Rockville, MD). The human cell lines men-
tioned above were cultured in complete RPMI 1640
medium (Life Technologies) supplemented with 10%
fetal bovine serum (Intergen). In general, the cell
lines were pretreated with various inhibitors for 1 h
before addition of PMA, manumycin, forskolin, oka-
daic acid and orthovanadate for an additional 8 h.
See the legends of the ¢gures for details.
2.3. Preparation of hPTP-J domain I probe by PCR
for Northern blot analysis
The PCR primers to amplify hPTP-J domain I
were designed as follows: sense primer: 5P-CGG-
GATCCCCACCGTCAACTACCGC-3P with Bam-
HI site-tailing, antisense primer: 5P-AGAATTCG-
GAGGAATTACTCTGAGG-3P with EcoRI site-
tailing. Using Jurkat T lymphoma cDNA as a tem-
plate, PCR was performed as follows: the ¢rst two
cycles: 94‡C for 1 min, 54‡C for 1 min and 72‡C for
1 min, then 30 cycles: 94‡C for 1 min, 65‡C for 1 min
and 72‡C for 1 min, the ¢nal cycle step: 94‡C for
1 min, 65‡C for 1 min and 72‡C for 10 min. The
resulting RT-PCR fragment (1.1 kb) was labeled
with a multiprime DNA labeling system (Amersham)
using [K-32P]dCTP as a speci¢c probe for detecting
hPTP-J mRNA.
2.4. RNA isolation and Northern blot analysis
Total RNAs were extracted from normal or stimu-
lated human tumor cell lines by the QuickPrep Total
RNA Extraction Kit (Pharmacia Biotech). Total
RNA of each sample (20 Wg) was electrophoresed
on a 1.0% agarose gel containing formaldehyde and
then transferred to a nylon membrane (Hybond-N,
Amersham). Hybridization was performed in a quick
hybridization solution (Stratagene), using a labeled
DNA fragment of hPTP-J domain I or human
L-actin as a probe according to the manufacturer’s
instructions.
3. Results
3.1. Kinetics and dose dependence of PMA-induced
down-regulation of hPTP-J transcription
In the previous study, the hPTP-J mRNA expres-
sion was down-regulated in Jurkat cells cultured with
PMA (50 ng/ml) for 24 or 36 h [14]. In order to
examine the kinetics of this down-regulation, Jurkat
cells were cultured with PMA for di¡erent periods of
time. As shown in Fig. 1, the transcription of hPTP-
J was completely blocked 8 h after the addition of
PMA (20 or 2 ng/ml) into the culture and transiently
up-regulated by 30 min after adding PMA (20 ng/
ml). We next examined the expression of hPTP-J
mRNA in Jurkat cells cultured for 8 h with various
concentrations of PMA (0.1^50 ng/ml). As shown in
Fig. 2, the down-regulation of the hPTP-J mRNA
expression induced by PMA was extremely sensitive
since the down-regulation was observed even in the
8 h culture with PMA (0.1 ng/ml). In order to inves-
tigate what signaling pathways/molecules are in-
volved in the transcriptional regulation of hPTP-J,
we used the culture conditions of 8 h and 20 ng/ml
PMA to induce the complete down-regulation of
hPTP-J transcription in the following experiments.
Fig. 1. Kinetics of regulation of hPTP-J mRNA levels by
PMA. Jurkat cells were cultured for varying periods of time
with PMA (2 or 20 ng/ml) as indicated. Hybridization was
done using the 32P-labeled DNA fragment of the hPTP-J do-
main I and L-actin as a control.
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3.2. Involvement of PKC in PMA-induced
down-regulation of hPTP-J expression
PMA, a potent PKC activator, induced the down-
regulation of hPTP-J transcription in Jurkat cells.
To investigate the role of PKC in the down-regula-
tion mechanism of hPTP-J transcription, Jurkat cells
were cultured with PKC inhibitors including H-7
(10 WM) and GF109203X (5 WM) or with other sig-
naling modulators 1 h before adding PMA to the
cultures. As shown in Fig. 3A, GF109203X or the
de novo protein synthesis inhibitor cycloheximide
(CHX, 10 Wg/ml) completely inhibited the PMA-in-
duced down-regulation of hPTP-J mRNA levels and
H-7 did so partially, but the other modulators in-
cluding the PTK inhibitor herbimycin A (Her-A,
Fig. 3. Involvement of PKC and new synthesized proteins in PMA-mediated regulation of hPTP-J mRNA expression. (A) Jurkat cells
were pretreated for 1 h with various inhibitors before addition of PMA (20 ng/ml) for an additional 8 h culture. (B) Jurkat cells were
cultured with PMA (20 ng/ml) for 20, 30 or 300 min with or without 1 h pretreatment with GF109203X and CHX.
Fig. 2. Concentration-dependent e¡ect of PMA on hPTP-J
mRNA accumulation. Jurkat cells were cultured with or with-
out graded concentrations (0.1^50 ng/ml) of PMA. After 8 h
culture, cells were lysed and total RNA was extracted. North-
ern blot was described in Section 2.
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500 ng/ml), the calmodulin-dependent kinase inhibi-
tor W-7 (20 WM), the cAMP-dependent protein ki-
nase inhibitor H-89 (5 WM), the Ras inhibitor manu-
mycin (Manu, 5 mM), the NF-UB inhibitor PDTC
(100 WM) [34] and the PI-3P kinase inhibitor wort-
mannin (Wort, 100 nM) had no e¡ects on the PMA-
induced down-regulation. The signaling modulators
used in this experiment did not a¡ect the basal levels
of hPTP-J expression in Jurkat cells except that H-
89, Manu and a higher concentration of wortmannin
(2.0 WM) down-regulated the basal levels of hPTP-J
expression in various degrees (data not shown). The
other inhibitors, including the Ca2-ATPase inhibi-
tor thapsigargin, the PTK inhibitor erbstatin and the
casein kinase II inhibitor heparin, had no e¡ects on
the PMA-induced down-regulation and the basal lev-
els of hPTP-J mRNA (data not shown).
We next analyzed the transient up-regulation of
hPTP-J transcription in Jurkat cells. As shown in
Fig. 3B, hPTP-J transcription was transiently up-
regulated 20 min and near completely down-regu-
lated 5 h after PMA addition. The short-term up-
regulation induced by PMA was blocked by
GF109203X but not by CHX, while the down-regu-
lation induced via PMA was blocked by both
GF109203X and CHX.
To further analyze the PKC-induced down-regula-
tory e¡ect, we used the exogenous activator of PKC,
OAG [9]. The hPTP-J mRNA levels were down-
regulated by culturing Jurkat cells with OAG (10
or 50 WM) for 8 h but the biologically inactive phor-
bol ester, 4K-PMA, as a negative control for PMA
had no e¡ect on the hPTP-J mRNA levels as shown
in Fig. 4A. A long-term treatment (48 h) of Jurkat
cells with OAG (50 WM) could not completely dimin-
ish hPTP-J expression since diacylglycerol exoge-
nously added was hydrolyzed quickly by DG lipase
and presumably by nonspeci¢c esterases [3,35], as
shown in Fig. 4B. Moreover, no e¡ect on the
PMA-induced down-regulation of hPTP-J expres-
sion was observed in the Jurkat cells cultured with
EDTA (3 mM) for 8 h, suggesting the extracellular
Ca2 is not essential for the down-regulation mech-
anism. Calcium ionophore slightly down-regulated
hPTP-J transcription (Fig. 4B).
3.3. Involvement of cAMP, Ras, PTP and PP1/PP2A
in the aberrant hPTP-J expression in T
lymphocytes
To examine whether hPTP-J expression was also
regulated by signaling pathways besides PKC, Jurkat
cells were treated with the adenylate cyclase stimula-
tor forskolin (10 nM), the Ras inhibitor Manu (1 WM
or 5 WM), the PTP inhibitor sodium orthovanadate
(100 WM) and the protein serine/threonine phospha-
tase (PP1 and PP2A) inhibitor okadaic acid (75 ng/
ml). As shown in Fig. 5A, 1 WM Manu and 10 nM
forskolin reduced nearly 80% of the hPTP-J tran-
scripts and higher doses of Manu (5 WM) and ortho-
vanadate (100 WM) completely blocked hPTP-J ex-
pression. To investigate the e¡ects of various
Fig. 4. E¡ect of OAG, 4K-PMA, or calcium ionophore on
hPTP-J mRNA accumulation. (A) Jurkat cells were cultured
for 8 h with OAG (10, 50 WM), 4K-PMA (20 ng/ml), PMA (20
ng/ml) or medium alone before total RNA extraction. (B) Jur-
kat cells were treated with OAG (10, 50 mM), Ca ionophore
(200 ng/ml), PMA (20 ng/ml) for various times as described in
Fig. 6B. Jurkat cells were pretreated with EDTA (3.0 mM) for
1 h before addition of PMA (20 ng/ml) for an additional 8 h.
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signaling modulators on the down-regulation of
hPTP-J expression induced by forskolin, Manu and
orthovanadate, Jurkat cells were cultured with the
various signaling modulators 1 h before adding for-
skolin, Manu or orthovanadate to the cultures. As
shown in Fig. 5B, the down-regulation of the hPTP-J
transcription induced by forskolin was blocked by
PKC inhibitors GF109203X and H-7, the calmodu-
lin-dependent kinase inhibitor W-7, the protein syn-
thesis inhibitor CHX and the cAMP-dependent pro-
tein kinase (PKA) inhibitor H-89 but was not
a¡ected by the PI-3P kinase inhibitor wortmannin
or the Ca2-ATPase inhibitor thapsigargin. As
shown in Fig. 5C, the Ras inhibitor-induced down-
regulation of hPTP-J expression was completely
blocked by CHX but not by GF109203X, H-7 and
H-89. The PTP inhibitor-mediated down-regulation
was not a¡ected by GF109203X, H-7 and CHX.
The down-regulation of hPTP-J transcription in-
duced by okadaic acid, a non-PMA-type tumor pro-
moter [36], showed similar kinetics as that induced
by PMA (data not shown), and the down-regulation
was blocked completely by CHX, largely by W-7 or
partially by thapsigargin as shown in Fig. 5D.
3.4. hPTP-J transcription was regulated as the same
pattern in Molt-4 cells as in Jurkat cells
To examine whether the down-regulation mecha-
nism of hPTP-J is common in the other hPTP-J-ex-
pressing cell lines, various tumor cell lines were ex-
amined by Northern blot analysis to determine the
other hPTP-J-expressing cell lines besides Jurkat T
cells. As shown in Fig. 6A, hPTP-J mRNA expres-
sion was strongly detected in Molt-4 but only weakly
6
Fig. 5. Transcription of hPTP-J was regulated by cAMP, Ras,
PTP and PP1- or PP2A-related pathways in Jurkat cells. (A)
Jurkat cells were treated with Manu (1, 5 WM), forskolin (10
nM), sodium orthovanadate (Na3VO4, 100 WM) or their combi-
nation with PMA for 8 h. (B) Jurkat cells were preincubated
with GF109203X (5 WM), H-7 (10 WM), CHX (10 Wg/ml) or H-
89 (5 WM), W-7 (20 WM), wortmannin (100 nM) and thapsigar-
gin (500 nM) before adding forskolin (10 nM) for 8 h. (C) Jur-
kat cells were pretreated with GF109203X (5 WM), H-7 (10
WM), CHX (10 Wg/ml) or H-89 (5 WM) before addition of
Manu (5 WM) or Na3VO4 (100 WM) for an additional 8 h. (D)
Jurkat cells were pretreated with GF109203X (5 WM), H-7 (10
WM), CHX (10 Wg/ml) or H-89 (5 WM), W-7 (20 WM), wort-
mannin (100 nM) and thapsigargin (500 nM), Manu (5 WM),
PDTC (100 WM) and Her-A (500 ng/ml) before adding okadaic
acid (75 ng/ml) for an additional 8 h incubation. Jurkat cells
were cultured in medium alone as a control.
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or not in U937, CCRF CEM, HL-60 and HUT 78
cell lines in comparison with the expression level of
Jurkat cells. The down-regulated transcription of
hPTP-J induced by culturing them with 20 ng/ml
PMA for 8 h was also observed in Molt-4 cells.
These results imply that a down-regulation mecha-
nism of hPTP-J expression by PMA is common in
Jurkat and Molt-4 cells. As shown in Fig. 6B, the
transcription of hPTP-J was down-regulated by
PMA and OAG, and the down-regulation was
blocked by GF109203X and CHX but not by Her-
A. Moreover, the transcription of hPTP-J was also
down-regulated by orthovanadate, forskolin and
okadaic acid (shown in Fig. 6C), and the down-reg-
ulation induced by Manu, a speci¢c Ras inhibitor,
was blocked via CHX but not GF109203X, H-7 and
H-89 (shown in Fig. 6D). These results suggest that
hPTP-J transcription was regulated via the same
mechanism in Jurkat and Molt-4 T lymphomas.
4. Discussion
In our previous work, we reported that the expres-
sion of a recently cloned new type II receptor-type
protein tyrosine phosphatase gene, hPTP-J, was un-
detectable in human peripheral blood lymphocytes
but highly expressed in the Jurkat T lymphoma cell
line. Moreover, hPTP-J transcription was down-
regulated by the tumor promoter PMA in Jurkat T
lymphoma cells but not by PHA and IL-2 [14]. Fur-
thermore, PTPQ, identical to a murine PTP-J, has
been demonstrated to associate with L-catenin via
the juxtamembrane domain [22], and L-catenin was
shown recently to be critical for tumorigenesis [29^
33].
The transcription of hPTP-J was completely
down-regulated by a low concentration of PMA
(0.5 ng/ml), suggesting that the down-regulation is
extremely sensitive to PMA compared with the opti-
mal PMA concentration (100 ng/ml) for T cell acti-
vation. Interestingly, the hPTP-J mRNA level was
Fig. 6. Transcription of hPTP-J was regulated by PKC, Ras,
PTP and PP1- or PP2A-related pathways in Molt-4 T cells. (A)
The various human tumor cell lines were treated with PMA (20
ng/ml) for 8 h, and 20 Wg each of total RNA prepared from
normal or PMA-treated cell lines were electrophoresed and
blotted on a nylon membrane. (B) Molt-4 cells were pretreated
for 1 h with GF109203X (5 WM), CHX (10 Wg/ml) and Her-A
(500 ng/ml) before adding PMA (20 ng/ml) or OAG (50 WM)
for an additional 8 h incubation. (C) Molt-4 cells were treated
with PMA (20 ng/ml), forskolin (10 nM), sodium orthovana-
date (Na3VO4, 100 WM) and okadaic acid (75 ng/ml) for 8 h.
(D) Molt-4 cells were pretreated for 1 h with GF109203X
(5 WM), H-7 (10 WM), CHX (10 Wg/ml) or H-89 (5 WM) before
addition of Manu (5 WM) for an additional 8 h incubation.
6
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transiently up-regulated 20 min after the addition of
PMA to the culture of Jurkat cells and thereafter
down-regulated to an undetectable level of hPTP-J
mRNA in 8 h after PMA addition as shown in Figs.
1 and 3B. The transient up-regulation induced by
PMA was blocked by the PKC-speci¢c inhibitor
GF109203X but not by the protein synthesis inhib-
itor CHX, while the down-regulation was blocked by
both GF109203X and CHX, suggesting that both
up- and down-regulation were induced via the acti-
vation of PKCs in a newly synthesized protein-inde-
pendent or -dependent manner, respectively. The
down-regulation of hPTP-J mRNA induced by
PMA was only partially blocked by another PKC
inhibitor, H-7. The di¡erential e¡ects of the PKC
inhibitors may be due to their inhibitory features.
Both GF109203X and H-7 can interact with the
ATP binding site of PKC, and thus inhibit the activ-
ities of total PKCs, but GF109203X is approximately
1000 times more sensitive than H-7. Moreover, H-7
can inhibit cAMP-dependent protein kinase and
cGMP-dependent protein kinase besides PKC [37].
The down-regulation of hPTP-J expression was
also induced by OAG, an exogenous activator of
PKC, but not by 4K-PMA, an inactive phorbol ester.
Therefore, these results strongly suggest that the
PMA-induced down-regulation of hPTP-J transcrip-
tion depends on a PKC-mediated pathway(s). Addi-
tionally, the involvement of PTK, NF-UB, PI-3P ki-
nase, calmodulin-dependent kinase, casein kinase II
and Ca2-ATPase was not critical in the regulation
mechanism.
Okadaic acid, a non-PMA type of tumor pro-
moter, can mimic PMA to regulate various cell lines
via di¡erent mechanisms [38,39]. In this study, the
down-regulation of hPTP-J transcription induced
by okadaic acid was blocked completely by CHX,
largely by the calmodulin-dependent kinase inhibitor
W-7 and partially by the Ca2-ATPase inhibitor
thapsigargin but was not a¡ected by the PKC inhib-
itor GF109203X as shown in Fig. 5D. Recently,
PP2A was found to associate with Ca2-calmodu-
lin-dependent protein kinase IV (CaMKIV) in a sta-
ble and stoichiometric manner and to function as a
negative regulator of the CaMKIV signal. The inhib-
ition of PP2A activity by okadaic acid, a potent
strong PP2A and weak PP1 inhibitor, enhanced ac-
tivation of the cAMP response element binding pro-
tein (CREB)-mediated transcription via the activa-
tion of CaMKIV [40]. Thus, the down-regulation of
hPTP-J transcription induced by okadaic acid is pos-
sibly via activation of CaMKIV since the down-reg-
ulation was mostly blocked by the CaMK inhibitor
W-7. This down-regulation induced by okadaic acid
may be partially via PP1 in a di¡erent mechanism.
Forskolin, an adenylate cyclase activator, increases
PLC-Q activity leading to the generation of diacylgly-
cerol and phosphoinositides in a PKA- and PKC-
dependent way [41]. Thus, it is not di⁄cult to under-
stand that the down-regulation of hPTP-J expression
induced by forskolin was blocked by GF109203X,
H-7, CHX and the PKA inhibitor H-89. As reported
before, forskolin inhibits the activity of protein ser-
ine-threonine phosphatase (PP) [42]. Therefore, the
down-regulation induced by forskolin is possibly
mediated by a similar mechanism as that induced
via okadaic acid since the down-regulation can be
blocked by the calmodulin-dependent kinase inhibi-
tor W-7.
Attachment of Ras protein to the membrane,
which requires farnesylation at its C-terminal
CAAX motif in a reaction catalyzed by protein far-
nesyltransferase (FTase), is essential for its biological
activity. Manu, an inhibitor of FTase, suppressed the
function of Ras, and the mutant Ras protein might
be more sensitive than wild-type Ras [43]. The hPTP-
J mRNA disappeared completely in the 8 h culture
of Jurkat cells with Manu (5 WM). The down-regu-
lation of hPTP-J transcription induced by Manu was
blocked by CHX. Thus, the results imply that con-
stitutive Ras may be essential for basic expression of
hPTP-J. Orthovanadate, an inhibitor of protein ty-
rosine phosphatases, acts potently as a promoter in
cell transformation. In addition to PMA and okadaic
acid, orthovanadate can cause hyperphosphorylation
of many cellular proteins by acceleration of phos-
phorylation and suppression of dephosphorylation
[44]. The down-regulation of hPTP-J transcription
induced by orthovanadate through the inhibition of
total PTPs was di¡erent from that induced by PMA,
Manu, forskolin or okadaic acid since the down-reg-
ulation was independent of PKC and de novo syn-
thesis proteins. Moreover, similar results were ob-
tained from Molt-4 T lymphoma cells as shown in
Fig. 6.
In conclusion, this study suggests that hPTP-J
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transcription is transiently up-regulated by the acti-
vation of PKC independently of newly synthesized
proteins, followed by completely down-regulation
by the activated PKC dependent on newly synthe-
sized proteins. The down-regulation of PTP-J tran-
scription induced by okadaic acid is possibly medi-
ated by the PP2A/CaMKIV pathway dependent on
newly synthesized proteins. Moreover, it is suggested
that the constitutive Ras and PTP are required for
the transcription of hPTP-J in Jurkat and Molt-4 T
lymphoma cell lines.
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